Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT05267080
Active, not recruiting Observational

Registry on Percutaneous Electrochemotherapy

NCT05267080 · tracked via the Priya Life Science Italy tracker
Sponsor
Cardiovascular and Interventional Radiological Society of Europe
Phase
Observational
Started
2023-01-25
Last updated
2026-02-06

Condition(s) studied

Primary Liver CancerSecondary Liver Cancer

Investigational drug(s) / intervention(s)

CLINIPORATOR

CLINIPORATOR: The CLINIPORATOR is used to perform percutaneous electrochemotherapy on liver tumours.

Study summary

The Registry on Percutaneous ElectroChemoTherapy (RESPECT) is a post-market, prospective, non-randomized, observational study aiming at evaluating the effectiveness of percutaneous electrochemotherapy (ECT) for the treatment of liver cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * 18 years or older * Primary or secondary liver cancer * Referral to local ablative treatment by multidisciplinary tumour board and decision to treat with pECT by interventional radiologist in charge * Planned treatment with pECT using the CLINIPORATOR * Signed informed consent form Exclusion Criteria: Pregnancy

Primary outcome measure(s)

  • Local Tumour Control — 12 months
    Based on the tumour status according to mRECIST assessment

Trial sites (15)

FacilityCityRegionStatus
Centre Hospitalier Universitaire de Montpellier Montpellier France
Hôpital Européen Georges-Pompidou Paris France
Institut Gustave Roussy Paris France
WEGE Klinik Bonn Germany
Städtisches Klinikum Braunschweig Braunschweig Germany
Universitätsklinikum Halle Halle Germany
Helios Park-Klinikum Leipzig Germany
University Hospital Regensburg Regensburg Germany
University of Szeged Szeged Hungary
Istituto Europeo di Oncologia Milan Italy
Fondazione Policlinico Universitario Campus Bio-Medico Rome Italy
Policlinico Universitario A. Gemelli Rome Italy
Vilnius University Hospital Santariškių Klinikos Vilnius Lithuania
Hospital Universitario y Politécnico La Fe Valencia Spain
Leeds Teaching Hospitals NHS Trust Leeds United Kingdom

Other trials for the same condition

The Dragon PLC Trial (DRAGON-PLC) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05267080 on ClinicalTrials.gov ↗ ← All trials in Italy